{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:13:32Z","timestamp":1782782012799,"version":"3.54.5"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>Cervical dystonia (CD), the most common focal dystonia encountered in neurologic practice, is a chronic disorder in which the muscles of the neck involuntarily contract and cause abnormal postures and movements of the head, neck, and shoulders. Treatment of CD prior to botulinum toxin was unsatisfactory, as existing therapies often did not improve symptoms. The use of botulinum toxin for CD grew out of its success in treating blepharospasm, another type of focal dystonia. On the basis of results from a double-blind, placebo-controlled trial, onabotulinumtoxinA was approved in 2000 in the US for the treatment of CD in adults in order to alleviate abnormal head position and neck pain. A subsequent large observational trial further demonstrated the effectiveness of onabotulinumtoxinA for CD, showing improvements in various rating scales, physician-reported measures, and profound positive effects on patient quality of life, including in amelioration of pain and improvements in work productivity. In addition, onabotulinumtoxinA treatment also reduced the complications of CD, as patients no longer develop contractures (permanent muscle and tendon shortening from prolonged untreated dystonia), which markedly limited the range of neck motion. The onset of onabotulinumtoxinA treatment also accompanied advances in understanding the functional anatomy of neck muscles, basal ganglia physiology, and video and other recording technology. Following the success of onabotulinumtoxinA in the treatment of CD, its use has been expanded into numerous other therapeutic indications, and these advances stimulated educational and training programs by various neurologic and other medical societies.<\/jats:p>","DOI":"10.1097\/md.0000000000032403","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:00:15Z","timestamp":1690484415000},"page":"e32403","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact"],"prefix":"10.1097","volume":"102","author":[{"given":"Joseph","family":"Jankovic","sequence":"first","affiliation":[{"name":"Parkinson\u2019s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tsui","sequence":"additional","affiliation":[{"name":"Division of Neurology, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[{"name":"Allergan\/AbbVie, Irvine, CA, USA"},{"name":"University of California, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240803","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: a consensus update.","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov Disord"},{"issue":"suppl 1","key":"R2-20240803","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0733-8619(08)80003-5","article-title":"Epidemiology, clinical presentation, and diagnosis of cervical dystonia.","volume":"26","author":"Stacy","year":"2008","journal-title":"Neurol Clin"},{"key":"R3-20240803","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00702-019-02116-7","article-title":"Frequency of different subtypes of cervical dystonia: a prospective multicenter study according to Col-Cap concept.","volume":"127","author":"Jost","year":"2020","journal-title":"J Neural Trans (Vienna)"},{"key":"R4-20240803","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.23011","article-title":"The phenomenology of the geste antagoniste in primary blepharospasm and cervical dystonia.","volume":"25","author":"Martino","year":"2010","journal-title":"Mov Disord"},{"key":"R5-20240803","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5334\/tohm.272","article-title":"Early illustrations of geste antagoniste in cervical and generalized dystonia.","volume":"5","author":"Broussolle","year":"2015","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"R7-20240803","first-page":"tre-03-193-4374-4372","article-title":"Descriptive epidemiology of cervical dystonia.","volume":"3","author":"Defazio","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/mds.25244","article-title":"The prevalence of primary dystonia: a systematic review and meta-analysis.","volume":"27","author":"Steeves","year":"2012","journal-title":"Mov Disord"},{"key":"R9-20240803","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00415-014-7343-6","article-title":"Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).","volume":"261","author":"Charles","year":"2014","journal-title":"J Neurol"},{"key":"R10-20240803","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mdc3.12238","article-title":"Impact of cervical dystonia on work productivity: an analysis from a patient registry.","volume":"3","author":"Molho","year":"2016","journal-title":"Mov Disord Clin Pract"},{"key":"R11-20240803","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/mds.22622","article-title":"Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status.","volume":"24","author":"Molho","year":"2009","journal-title":"Mov Disord"},{"key":"R12-20240803","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S0317167100044139","article-title":"Anticholinergics in adult-onset focal dystonia.","volume":"9","author":"Lang","year":"1982","journal-title":"Can J Neurol Sci"},{"key":"R13-20240803","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S0317167100023830","article-title":"Pathophysiology and pharmacotherapy of spasmodic torticollis: a review.","volume":"6","author":"Lal","year":"1979","journal-title":"Can J Neurol Sci"},{"issue":"12 suppl 5","key":"R14-20240803","first-page":"S9","article-title":"Pharmacological and surgical options for the treatment of cervical dystonia.","volume":"55","author":"Adler","year":"2000","journal-title":"Neurology"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/brain\/121.4.547","article-title":"Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia.","volume":"121","author":"Dauer","year":"1998","journal-title":"Brain"},{"key":"R16-20240803","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp.47.11.1166","article-title":"The treatment of severe dystonia in children and adults.","volume":"47","author":"Marsden","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R17-20240803","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/jnnp.63.6.788","article-title":"Clinical features and natural history of axial predominant adult onset primary dystonia.","volume":"63","author":"Bhatia","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R18-20240803","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0090-3019(93)90118-K","article-title":"Selective peripheral denervation for spasmodic torticollis: surgical technique, results, and observations in 260 cases.","volume":"40","author":"Bertrand","year":"1993","journal-title":"Surg Neurol"},{"key":"R19-20240803","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/jnnp.58.2.258","article-title":"Treatment of spasmodic torticollis with intramuscular phenol injection.","volume":"58","author":"Massey","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R20-20240803","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.apmr.2003.10.012","article-title":"Phenol block for cervical dystonia: effects and side effects.","volume":"85","author":"Takeuchi","year":"2004","journal-title":"Arch Phy Med Rehabil"},{"key":"R22-20240803","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1146\/annurev-biochem-013118-111654","article-title":"Botulinum and tetanus neurotoxins.","volume":"88","author":"Dong","year":"2019","journal-title":"Ann Rev Biochem"},{"key":"R23-20240803","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.","volume":"87","author":"Scott","year":"1980","journal-title":"Ophthalmology"},{"key":"R24-20240803","first-page":"734","article-title":"Botulinum toxin injection of eye muscles to correct strabismus.","volume":"79","author":"Scott","year":"1981","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R25-20240803","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archopht.1985.01050030043017","article-title":"Botulinum A toxin injection as a treatment for blepharospasm.","volume":"103","author":"Scott","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"R26-20240803","first-page":"367","article-title":"Management of blepharospasm.","volume":"83","author":"Waller","year":"1985","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R27-20240803","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/archopht.1984.01040031184014","article-title":"Treatment of blepharospasm with botulinum toxin: a preliminary report.","volume":"102","author":"Frueh","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"R28-20240803","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"R29-20240803","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study.","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"key":"R30-20240803","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1017\/S031716710003540X","article-title":"A pilot study on the use of botulinum toxin in spasmodic torticollis.","volume":"12","author":"Tsui","year":"1985","journal-title":"Can J Neurolog Sci"},{"key":"R31-20240803","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/mds.870120117","article-title":"Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin.","volume":"12","author":"Tarsy","year":"1997","journal-title":"Mov Disord"},{"key":"R32-20240803","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","article-title":"Double-blind study of botulinum toxin in spasmodic torticollis.","volume":"328","author":"Tsui","year":"1986","journal-title":"Lancet"},{"key":"R33-20240803","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870020402","article-title":"Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.","volume":"2","author":"Brin","year":"1987","journal-title":"Mov Disord"},{"key":"R34-20240803","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/WNL.40.2.277","article-title":"Botulinum toxin injections for cervical dystonia.","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"issue":"3 suppl","key":"R35-20240803","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1017\/S0317167100038063","article-title":"Local treatment of spasmodic torticollis with botulinum toxin.","volume":"14","author":"Tsui","year":"1987","journal-title":"Can J Neurolog Sci"},{"key":"R37-20240803","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/WNF.0b013e31826538c7","article-title":"Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia.","volume":"35","author":"Charles","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"R38-20240803","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2377-11-140","article-title":"Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).","volume":"11","author":"Jankovic","year":"2011","journal-title":"BMC Neurol"},{"key":"R39-20240803","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2014.12.030","article-title":"Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE).","volume":"349","author":"Jankovic","year":"2015","journal-title":"J Neurolog Sci"},{"key":"R40-20240803","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/papr.12408","article-title":"Neck pain and cervical dystonia: treatment outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).","volume":"16","author":"Charles","year":"2016","journal-title":"Pain Pract"},{"key":"R41-20240803","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2377-14-91","article-title":"Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia.","volume":"14","author":"Marsh","year":"2014","journal-title":"BMC Neurol"},{"key":"R42-20240803","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence.","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"R43-20240803","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.toxicon.2014.07.009","article-title":"Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up.","volume":"90","author":"Ramirez-Castaneda","year":"2014","journal-title":"Toxicon"},{"key":"R44-20240803","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins.","volume":"120","author":"Naumann","year":"2013","journal-title":"J Neural Transm (Vienna)"},{"key":"R45-20240803","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/toxins11090491","article-title":"Immunogenicity associated with botulinum toxin treatment.","volume":"11","author":"Bellows","year":"2019","journal-title":"Toxins"},{"key":"R46-20240803","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.","volume":"23","author":"Brin","year":"2008","journal-title":"Mov Disord"},{"key":"R47-20240803","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"R48-20240803","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF03033933","article-title":"Botulinum toxin therapy for cervical dystonia.","volume":"9","author":"Jankovic","year":"2006","journal-title":"Neurotox Res"},{"key":"R49-20240803","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/toxins5020249","article-title":"Long-term efficacy and safety of botulinum toxin injections in dystonia.","volume":"5","author":"Ramirez-Castaneda","year":"2013","journal-title":"Toxins"},{"key":"R50-20240803","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/toxins13010042","article-title":"Botulinum toxin in movement disorders: an update.","volume":"13","author":"Anandan","year":"2021","journal-title":"Toxins"},{"key":"R51-20240803","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.27072","article-title":"Botulinum toxin: state of the art.","volume":"32","author":"Jankovic","year":"2017","journal-title":"Mov Disord"},{"key":"R52-20240803","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.toxicon.2017.09.003","article-title":"An update on new and unique uses of botulinum toxin in movement disorders.","volume":"147","author":"Jankovic","year":"2018","journal-title":"Toxicon"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:55:52Z","timestamp":1722736552000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":49,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032403","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}